Photo - KAREL
49077

KAREL

Remote monitoring for Chronic Kidney Disease

Australia
Market: Medicine, Services, Mobile applications
Stage of the project: Prototype or product is ready

Date of last change: 04.09.2020
Rating
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:

Idea

KAREL helps patients and clinicians share and manage behaviour change, empowering them to take control of disease progression and end the need for dialysis and kidney transplants.

Current Status

- During our market and clinical research, we seeded a market before we even had a product
- Product is now LIVE in app stores worldwide for patients
- 20 future pilot hospitals and patient app users in 30 countries





Market

Core customer segments

Clinicians
- Kidney doctors, nurse, and hospitals

Patients
- From early-stage all the way through to dialysis. In our key markets of USA, UK, Canada, Australia, and NZ there are millions of patients

Partners
- A mix of different pharma, insurance, and private health partners we are speaking to

Problem or Opportunity

Clinicians struggle to deliver the care kidney patients need

Solution (product or service)

Meet KAREL
A one-stop-shop, remote monitoring solution for Kidney disease

Helping patients easily take control of their CKD journey‍ with tools to manage their everyday life with an app.

Empowering clinicians with a 360 view of the patient experience to deliver high-quality online care outside of the clinic.





Competitors

Renalmate (US focused) > https://renalmate.com/
PatientMpower (also focus on Lung Disease) > https://info.patientmpower.com/
Current Health (disease agnostic) > https://currenthealth.com/

Advantages or differentiators

Renalmate
> https://renalmate.com/
- Advantage - Pivoted from lifestyle wellness into kidney health so has experience in behaviour change of patients
- Disadvantages - Their business model will struggle in public health markets outside the USA which KAREL has a strong focus

PatientMpower
> https://info.patientmpower.com/
- Advantage - A few years ahead of our team and already embedded in a few hospitals across Europe (specifically Ireland)
- Disadvantage - Have pivoted into Lung Health making their proposition less enticing for kidney patients

Current Health
> https://currenthealth.com/
- Advantage - Strong investment to date with a very robust team of 40+ people
- Disadvantage - As their platform is disease agnostic it will be less competitive in response to Kidney Health needs

Finance

Business model: SaaS to providers & Freemium to patients
We charge hospitals $10 per patient per month to retain our remote monitoring software.

Go to market & revenue streams
Patients:
Freemium revenue

Hospitals:
Key account strategy
SaaS revenue

Tech partnership (e,g connected devices)
Revenue share
Connected devices

Pharma
Research content
Clinical trials
SaaS/Revenue share

Business model

Business model: SaaS to providers & Freemium to patients
We charge hospitals $10 per patient per month to retain our remote monitoring software.

Go to market & revenue streams
Patients:
Freemium revenue

Hospitals:
Key account strategy
SaaS revenue

Tech partnership (e,g connected devices)
Revenue share
Connected devices

Pharma
Research content
Clinical trials
SaaS/Revenue share

Money will be spent on

Patient community - scaling of app product (20%)
Clinical trials - in partnership with hospitals (10%)
IoHT & integration / product roadmap - (60%)
Governance - ensuring our healthtech software is top tier in security (10%)

Offer for investor

‍Our mission is to stop CKD patients ever needing dialysis or transplants.

‍And with your help, we can make it happen.

Invest in helping people
Chronic kidney disease is one of the fastest-growing health problems in the world Globally, CKD is projected to be the fifth most common cause of mortality by 2040. Now is the time to get ahead of the curve. And KAREL is looking for investment partners who want to make it happen.

Join us on our mission to take on this silent killer. In the process, we’ll save healthcare systems some of the $130 billion spent each year on CKD by empowering hundreds of millions of patients around the world through self-managed care.

Team or Management

Risks

- COVID19 hitting hard again and limiting hospital interaction

Incubation/Acceleration programs accomplishment

None

Won the competition and other awards

Finalist
Startmate 2020 program in Australia > https://www.startmate.com.au/

Winner:
StartupVIC pitchfest > https://startupvictoria.com.au/
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility109
star0
Add to favorites
Delete from favorites
share
close
thumb_up5
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video